Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Australia ,Taiwan ,United States ,California ,Taipei ,T Ai Pei ,San Diego ,South Korea ,Canada ,Senhwa Biosciences Tpex ,Mei Hui Kuo ,Senhwa Biosciences ,Senhwa Bioscience ,Senhwa Biosciences Inc ,Company Codes ,Drug Administration ,Orphan Drug Designation ,Biliary Tract ,Biliary Tract Cancer ,Acting Chief Executive Officer ,Rare Pediatric Disease Designation ,Fast Track Designation ,Sonic Hedgehog ,Resume ,Careers ,Enhwa 39s Silmitasertib Receives Us Fda Orphan Drug Designation For The Treatment Of Biliary Tract Cancer ,Iospace ,Advice ,